Comparative Pharmacology
Head-to-head clinical analysis: IFOSFAMIDE versus TREANDA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IFOSFAMIDE versus TREANDA.
IFOSFAMIDE vs TREANDA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Prodrug activated by cytochrome P450 to cytotoxic metabolites (4-hydroxyifosfamide, acrolein, and ifosforamide mustard) that alkylate DNA by cross-linking guanine bases, inhibiting DNA replication and transcription.
Bendamustine is a bifunctional mechlorethamine derivative that forms electrophilic alkyl groups which covalently bond to DNA bases, resulting in interstrand DNA crosslinks, DNA single- and double-strand breaks, and ultimately apoptosis. It also inhibits several mitotic checkpoints and induces both apoptosis and necrosis in cancer cells.
1.2 g/m² IV over 2 hours daily for 5 consecutive days every 3 weeks, or 5 g/m² IV as a 24-hour continuous infusion every 3 weeks. Administer with mesna and vigorous hydration.
120 mg/m2 IV over 60 minutes on Days 1 and 2 of a 21-day cycle.
None Documented
None Documented
Clinical Note
moderateIfosfamide + Digoxin
"Ifosfamide may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateIfosfamide + Digitoxin
"Ifosfamide may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateIfosfamide + Deslanoside
"Ifosfamide may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateIfosfamide + Acetyldigitoxin
"Ifosfamide may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal half-life: 4-7 hours for parent drug; active metabolite 4-desulfonate has half-life ~12-15 hours. Clinical context: Prolonged with renal impairment.
Terminal elimination half-life: ~36-40 minutes (active metabolite M3: ~3 hours). Short half-life supports multi-day dosing regimens; clinical effect duration is longer due to DNA alkylation.
Primarily renal: 50-60% excreted unchanged in urine. Biliary/fecal excretion is minimal (<5%).
Renal: ~50% as unchanged drug and metabolites; additional biliary/fecal elimination (non-renal clearance accounts for ~50% in humans, but specific biliary/fecal percentages not routinely quantified in clinical studies).
Category D/X
Category C
Alkylating Agent
Alkylating Agent